Document is current
Any future updates will be listed below
-
Authors
Alves, Inês https://orcid.org/0000-0001-8963-4736
Fredwall, Svein Otto https://orcid.org/0000-0002-2804-5783
Hughes, Michael
Ireland, Penelope J. https://orcid.org/0000-0002-9619-9071
Kaisermann, Morrys C. https://orcid.org/0000-0002-6495-022X
Savarirayan, Ravi https://orcid.org/0000-0002-5105-8427
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 24 December 2025
First Online: 20 January 2026
Declarations
:
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
: Not applicable.
: IA and PI have no competing interests to report. SOF has received consulting fees from BioMarin paid to his institution and is an investigator in clinical trials for Ascendis Pharma A/S and QED Therapeutics. MH has no competing interests relevant to this publication but reports that he is an employee of Merck; Merck has no commercial or research involvement in achondroplasia. MCK has no competing interests relevant to this publication but reports that he is an employee of GlaxoSmithKline; GlaxoSmithKline had no involvement in this work. RS has received consulting fees and grants from BioMarin and was an investigator in clinical trials for achondroplasia for Ascendis Pharma A/S, BioMarin, and QED Therapeutics.
